eating disorders | CARLAT PUBLISHING

RESEARCH UPDATE

Therapist Bonds Improve Loss-of-Control Eating

December 9, 2024

Jennifer Leavitt, MS. PhD(c)

Jennifer Leavitt, MS. PhD(c). Ms. Leavitt has no financial relationships with companies related to this material.

This study reveals whether a strong therapist bond can improve outcomes for adolescents with eating disorders.

Clinical Update

Binge Eating Disorder: Management and Treatment Options

November 9, 2023

Michael Posternak, MD.

Michael Posternak, MD.

At the time of writing, Dr. Posternak had no financial relationships with companies related to this material.

We regret that Dr. Posternak passed away after finishing this piece. He had a warm heart, a bright mind, and a keen eye for the needs of psychiatric patients.

We have one FDA-approved treatment for binge eating disorder (Vyvanse), but therapy is first line, and there are practical ways to start that process during a medication visit. We also cover off-label medications for times when a stimulant is not a good choice.

BOOK REVIEWS FOR PSYCHIATRISTS

A Review of I’m Glad My Mom Died

May 22, 2023

Emily E. Whisler, DO and Edmund S. Higgins, MD.

Sometimes it takes more than psychotherapy and medications to break familial patterns.

Clinical Update

The Medical Evaluation of Anorexia

February 1, 2023

Chris Aiken, MD and Garrett Rossi, MD.

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.
Garrett Rossi, MD. Adult psychiatrist, AtlantiCare Regional Medical Center, Pomona, NJ.

Dr. Aiken and Dr. Rossi have no financial relationships with companies related to this material.

When do you order labs, how do you weight patients, and what signs and symptoms should prompt a higher level of care?

RESEARCH UPDATE

SSRIs and Hydroxyzine for Avoidant/Restrictive Food Intake Disorder (ARFID)?

October 1, 2022

Joshua Feder, MD

Dr. Feder, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Clinicians use olanzapine, mirtazapine, and other appetite-inducing medications off label to treat ARFID, but with little research to support their use. This study unpacks the potential role of medications in treating comorbid symptoms associated with ARFID.

Addressing Weight Stigma in Clinical Practice

September 19, 2022

Joshua Feder, MD and Mara Goverman

Every patient and family you see is inescapably impacted by weight stigma or fat shaming and the damage from this bias can lethal.

Diagnosing and Treating Avoidant/Restrictive Food Intake Disorder

August 8, 2022

Joshua Feder, MD, Mara Goverman, and Jennifer Thomas, PhD

Nine years after DSM-5, Avoidant Restrictive Food Intake Disorder (ARFID) is still settling into clinical practice. Dr. Jennifer Thomas helps sort out the differential diagnosis between ARFID, anorexia, and other conditions and plan treatment in the context of comorbid conditions, such as anxiety disorders and Autism Spectrum Disorder.

RESEARCH UPDATE

New Canadian Eating Disorders Guidelines

March 12, 2021

John Raiss, MD

John Raiss, MD Dr. Raiss has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

What is the best approach to treatment of adolescents with eating disorders? What level of care should be we advocating for to have the best chance of a good outcome? This review of the recent Canadian Eating Disorders Guidelines offers a clear direction for our efforts to provide better care.

RESEARCH UPDATE

Olanzapine for Anorexia Nervosa

November 15, 2019

Kristen Gardner, PharmD.

Kristen Gardner, PharmD. Dr. Gardner has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

A randomized, double- blind, placebo-controlled trial studying the effects of olanzapine on change in body weight and obsessionality in adult outpatients with anorexia nervosa. Although strength of the study includes its large sample size, it is undetermined if patient weight gain is due to a therapeutic effect on anorexia or to olanzapine’s known metabolic effects.